Global Paroxysmal Supraventricular Tachycardia Market Size, Status and Forecast 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 98

Report ID: 19500

Paroxysmal supraventricular tachycardia (PSVT) is a type of supraventricular tachycardia. Often people have no symptoms. Otherwise symptoms may include palpitations, feeling lightheaded, sweating, shortness of breath, and chest pain. Episodes start and end suddenly.
About 2.3 per 1000 people have paroxysmal supraventricular tachycardia. Problems typically begin in those 12 to 45 years old. Women are more often affected than men. Outcomes in those who otherwise have a normal heart are generally good. An ultrasound of the heart may be done to rule out underlying heart problems.
In 2018, the global Paroxysmal Supraventricular Tachycardia market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Paroxysmal Supraventricular Tachycardia status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Paroxysmal Supraventricular Tachycardia development in United States, Europe and China.

The key players covered in this study
GlaxoSmithKline
Sanofi
Pfizer
Novartis International
Teva Pharmaceutical Industries
Medtronic
Glenmark Pharmaceuticals
St. Jude Medical
Boston Scientific

Market segment by Type, the product can be split into
AV Nodal Re-Entrant Tachycardia (AVNRT)
AV Reciprocating Tachycardia (AVRT)
Paroxysmal Atrial Tachycardia (PAT)
Wolff-Parkinson-White Syndrome (WPW)

Market segment by Application, split into
Hospitals & Clinics
Diagnostic Centers
Medical Research Centers

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Paroxysmal Supraventricular Tachycardia status, future forecast, growth opportunity, key market and key players.
To present the Paroxysmal Supraventricular Tachycardia development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Paroxysmal Supraventricular Tachycardia are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Paroxysmal Supraventricular Tachycardia Market Size Growth Rate by Type (2014-2025)
1.4.2 AV Nodal Re-Entrant Tachycardia (AVNRT)
1.4.3 AV Reciprocating Tachycardia (AVRT)
1.4.4 Paroxysmal Atrial Tachycardia (PAT)
1.4.5 Wolff-Parkinson-White Syndrome (WPW)
1.5 Market by Application
1.5.1 Global Paroxysmal Supraventricular Tachycardia Market Share by Application (2014-2025)
1.5.2 Hospitals & Clinics
1.5.3 Diagnostic Centers
1.5.4 Medical Research Centers
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Paroxysmal Supraventricular Tachycardia Market Size
2.2 Paroxysmal Supraventricular Tachycardia Growth Trends by Regions
2.2.1 Paroxysmal Supraventricular Tachycardia Market Size by Regions (2014-2025)
2.2.2 Paroxysmal Supraventricular Tachycardia Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Paroxysmal Supraventricular Tachycardia Market Size by Manufacturers
3.1.1 Global Paroxysmal Supraventricular Tachycardia Revenue by Manufacturers (2014-2019)
3.1.2 Global Paroxysmal Supraventricular Tachycardia Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Paroxysmal Supraventricular Tachycardia Market Concentration Ratio (CR5 and HHI)
3.2 Paroxysmal Supraventricular Tachycardia Key Players Head office and Area Served
3.3 Key Players Paroxysmal Supraventricular Tachycardia Product/Solution/Service
3.4 Date of Enter into Paroxysmal Supraventricular Tachycardia Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Paroxysmal Supraventricular Tachycardia Market Size by Type (2014-2019)
4.2 Global Paroxysmal Supraventricular Tachycardia Market Size by Application (2014-2019)

5 United States
5.1 United States Paroxysmal Supraventricular Tachycardia Market Size (2014-2019)
5.2 Paroxysmal Supraventricular Tachycardia Key Players in United States
5.3 United States Paroxysmal Supraventricular Tachycardia Market Size by Type
5.4 United States Paroxysmal Supraventricular Tachycardia Market Size by Application

6 Europe
6.1 Europe Paroxysmal Supraventricular Tachycardia Market Size (2014-2019)
6.2 Paroxysmal Supraventricular Tachycardia Key Players in Europe
6.3 Europe Paroxysmal Supraventricular Tachycardia Market Size by Type
6.4 Europe Paroxysmal Supraventricular Tachycardia Market Size by Application

7 China
7.1 China Paroxysmal Supraventricular Tachycardia Market Size (2014-2019)
7.2 Paroxysmal Supraventricular Tachycardia Key Players in China
7.3 China Paroxysmal Supraventricular Tachycardia Market Size by Type
7.4 China Paroxysmal Supraventricular Tachycardia Market Size by Application

8 Japan
8.1 Japan Paroxysmal Supraventricular Tachycardia Market Size (2014-2019)
8.2 Paroxysmal Supraventricular Tachycardia Key Players in Japan
8.3 Japan Paroxysmal Supraventricular Tachycardia Market Size by Type
8.4 Japan Paroxysmal Supraventricular Tachycardia Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Paroxysmal Supraventricular Tachycardia Market Size (2014-2019)
9.2 Paroxysmal Supraventricular Tachycardia Key Players in Southeast Asia
9.3 Southeast Asia Paroxysmal Supraventricular Tachycardia Market Size by Type
9.4 Southeast Asia Paroxysmal Supraventricular Tachycardia Market Size by Application

10 India
10.1 India Paroxysmal Supraventricular Tachycardia Market Size (2014-2019)
10.2 Paroxysmal Supraventricular Tachycardia Key Players in India
10.3 India Paroxysmal Supraventricular Tachycardia Market Size by Type
10.4 India Paroxysmal Supraventricular Tachycardia Market Size by Application

11 Central & South America
11.1 Central & South America Paroxysmal Supraventricular Tachycardia Market Size (2014-2019)
11.2 Paroxysmal Supraventricular Tachycardia Key Players in Central & South America
11.3 Central & South America Paroxysmal Supraventricular Tachycardia Market Size by Type
11.4 Central & South America Paroxysmal Supraventricular Tachycardia Market Size by Application

12 International Players Profiles
12.1 GlaxoSmithKline
12.1.1 GlaxoSmithKline Company Details
12.1.2 Company Description and Business Overview
12.1.3 Paroxysmal Supraventricular Tachycardia Introduction
12.1.4 GlaxoSmithKline Revenue in Paroxysmal Supraventricular Tachycardia Business (2014-2019)
12.1.5 GlaxoSmithKline Recent Development
12.2 Sanofi
12.2.1 Sanofi Company Details
12.2.2 Company Description and Business Overview
12.2.3 Paroxysmal Supraventricular Tachycardia Introduction
12.2.4 Sanofi Revenue in Paroxysmal Supraventricular Tachycardia Business (2014-2019)
12.2.5 Sanofi Recent Development
12.3 Pfizer
12.3.1 Pfizer Company Details
12.3.2 Company Description and Business Overview
12.3.3 Paroxysmal Supraventricular Tachycardia Introduction
12.3.4 Pfizer Revenue in Paroxysmal Supraventricular Tachycardia Business (2014-2019)
12.3.5 Pfizer Recent Development
12.4 Novartis International
12.4.1 Novartis International Company Details
12.4.2 Company Description and Business Overview
12.4.3 Paroxysmal Supraventricular Tachycardia Introduction
12.4.4 Novartis International Revenue in Paroxysmal Supraventricular Tachycardia Business (2014-2019)
12.4.5 Novartis International Recent Development
12.5 Teva Pharmaceutical Industries
12.5.1 Teva Pharmaceutical Industries Company Details
12.5.2 Company Description and Business Overview
12.5.3 Paroxysmal Supraventricular Tachycardia Introduction
12.5.4 Teva Pharmaceutical Industries Revenue in Paroxysmal Supraventricular Tachycardia Business (2014-2019)
12.5.5 Teva Pharmaceutical Industries Recent Development
12.6 Medtronic
12.6.1 Medtronic Company Details
12.6.2 Company Description and Business Overview
12.6.3 Paroxysmal Supraventricular Tachycardia Introduction
12.6.4 Medtronic Revenue in Paroxysmal Supraventricular Tachycardia Business (2014-2019)
12.6.5 Medtronic Recent Development
12.7 Glenmark Pharmaceuticals
12.7.1 Glenmark Pharmaceuticals Company Details
12.7.2 Company Description and Business Overview
12.7.3 Paroxysmal Supraventricular Tachycardia Introduction
12.7.4 Glenmark Pharmaceuticals Revenue in Paroxysmal Supraventricular Tachycardia Business (2014-2019)
12.7.5 Glenmark Pharmaceuticals Recent Development
12.8 St. Jude Medical
12.8.1 St. Jude Medical Company Details
12.8.2 Company Description and Business Overview
12.8.3 Paroxysmal Supraventricular Tachycardia Introduction
12.8.4 St. Jude Medical Revenue in Paroxysmal Supraventricular Tachycardia Business (2014-2019)
12.8.5 St. Jude Medical Recent Development
12.9 Boston Scientific
12.9.1 Boston Scientific Company Details
12.9.2 Company Description and Business Overview
12.9.3 Paroxysmal Supraventricular Tachycardia Introduction
12.9.4 Boston Scientific Revenue in Paroxysmal Supraventricular Tachycardia Business (2014-2019)
12.9.5 Boston Scientific Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details